ESR1 and breast cancer: A phase II study (PALOMA-1/TRIO-18) in patients with newly diagnosed ER-positive, HER2-negative advanced breast cancer demonstrated significantly longer PFS (20.2 versus 10.2 months) with palbociclib and letrozole treatment compared to letrozole alone [20].